Case Control Study
Copyright ©The Author(s) 2023.
World J Gastrointest Surg. Jul 27, 2023; 15(7): 1340-1353
Published online Jul 27, 2023. doi: 10.4240/wjgs.v15.i7.1340
Figure 1
Figure 1 Survival comparisons between the combined hepatocellular and cholangiocarcinoma and hepatocellular carcinoma groups. A: Cumulative disease-free survival; B: Cumulative overall survival; C: Cumulative disease-free survival after propensity score matching; D: Cumulative oval survival after propensity score matching. HCC: Hepatocellular carcinoma; CC: Cholangiocarcinoma; HCC-CC: Hepatocellular carcinoma-cholangiocarcinoma.
Figure 2
Figure 2 Survival comparisons between the combined hepatocellular and cholangiocarcinoma and hepatocellular carcinoma groups of patients within the Milan criteria. A: Cumulative disease-free survival; B: Cumulative overall survival; C: Cumulative disease-free survival after propensity score matching; D: Cumulative oval survival after propensity score matching. HCC: Hepatocellular carcinoma; CC: Cholangiocarcinoma; HCC-CC: Hepatocellular carcinoma-cholangiocarcinoma.
Figure 3
Figure 3 Survival comparisons between the combined hepatocellular and cholangiocarcinoma and hepatocellular carcinoma groups of patients beyond the Milan criteria. A: Cumulative disease-free survival; B: Cumulative overall survival; C: Cumulative disease-free survival after propensity score matching; D: Cumulative oval survival after propensity score matching. HCC: Hepatocellular carcinoma; CC: Cholangiocarcinoma; HCC-CC: Hepatocellular carcinoma-cholangiocarcinoma.